Immunohistochemical similarities between pancreatic mucinous cystic tumor and ovarian mucinous cystic tumor

Pancreas

Volumn 36, Issue 1, 2008, Pages

  Suzuki, Yutaka ^a   Sugiyama, Masanori ^a   Abe, Nobutsugu ^a   Fujioka, Yasunori ^a   Atomi, Yutaka ^a  

^a KYORIN UNIVERSITY   (Japan)

Author keywords

Cell cycle regulators; Female sex hormone markers; Imunohistochemical study; Ovarian mucinous cystic tumor; Pancreatic mucinous cystic tumor; Pancreatobiliary tissue markers

Indexed keywords

CA 19-9 ANTIGEN; CYCLIN DEPENDENT KINASE INHIBITOR 1B; DUPAN 2; ESTROGEN RECEPTOR; INHIBIN A; PROGESTERONE RECEPTOR;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CLINICAL FEATURE; CONTROLLED STUDY; CYSTADENOMA; DIAGNOSTIC PROCEDURE; DIFFERENTIAL DIAGNOSIS; FEMALE; HORMONE BLOOD LEVEL; HUMAN; IMMUNOHISTOCHEMISTRY; LABORATORY TEST; OVARY CYST; PANCREAS ADENOMA; PHYSICAL EXAMINATION; PRIORITY JOURNAL; PROTEIN EXPRESSION; STROMA CELL;

ADULT; AGED; CARCINOMA, PANCREATIC DUCTAL; CYCLIN-DEPENDENT KINASE INHIBITOR P27; CYSTADENOCARCINOMA, MUCINOUS; CYSTADENOMA, MUCINOUS; EPITHELIAL CELLS; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; INHIBINS; MIDDLE AGED; OVARIAN NEOPLASMS; PANCREATIC NEOPLASMS; RECEPTORS, ESTROGEN; RECEPTORS, PROGESTERONE;

EID: 38149046640     PISSN: 08853177     EISSN: None     Source Type: Journal    
DOI: 10.1097/mpa.0b013e3181584643     Document Type: Article

References (27)

1. Compagno J, Oertel JE. Mucinous cystic neoplasms of the pancreas with overt and latent malignancy (cystadenocarcinoma and cystadenoma). Clinicopathologic study of 41 cases. Am J Clin Pathol. 1978;69:573-580.
2. Solcia E, Capella C, Loppel G, et al. Tumor of the Pancreas. Atlas of Tumor Pathology. 3rd series, Fascicle 20. Washington, DC: Armed Forces Institute of Pathology; 1997.
3. Thompson LD, Becker RC, Przygodski RM, et al. Mucinous cystic neoplasm (mucinous cystadenocarcinoma of low-grade malignant potential) of the pancreas. Am J Surg Pathol. 1999;23:1-16.
4. Zamboni G, Scarpa A, Bogina G, et al. Mucinous cystic tumor of the pancreas. Am J Surg Pathol. 1999;23:410-422.
5. Klöppel G, Solcia E, Longnecker DS, et al. Histological Typing of Tumors of the Exocrine Pancreas. Berlin: WHO, Springer; 1996.
6. Ridder GJ, Mascheck H, Flemming P, et al. Ovarian-like stroma in and invasive mucinous cystadenocarcinoma of the pancreas positive for inhibin. A hint concerning its possible histogenesis. Virchows Arch. 1998;432:451-454.
7. Scully R, Young RH, Path FRC, et al. Tumor of the Ovary, Maldeveloped Gonads, Fallopian Tube and Broad Ligament. Atlas of Tumor Pathology. 3rd series, Fascicle 20. Washington, DC: Armed Forces Institute of Pathology; 1997.
8. Japan Pancreas Society. Classification of Pancreatic Carcinoma. 2nd English ed., Tokyo: Kanehara & Co., Ltd.; 2003.
9. Japan Society of Obstetrics and Gynecology and The Japanese Society of Pathology. The General Rules for Clinical and Pathological Management of Ovarian Tumors. Tokyo: Kanehara & Co., Ltd.; 1990.
10. Izumo A, Yamaguchi K, Eguchi T, et al. Mucinous cystic tumor of the pancreas: Immunohistochemical assessment of "ovarian-type stroma". Oncol Rep. 2003;10:515-525.
11. Burger HG. Inhibin. Reprod Rev. 1992;1:1-20.
12. Burger HG. Evidence for a negative feedback role of inhibin in follicle-stimulating hormone regulation in women. Hum Reprod. 1993; 8:129-132.
13. Gurusinghe CJ, Healy DL, Jobling T, et al. Inhibin and activin are demonstrable by immunohistochemistry in ovarian tumor tissue. Gynecol Oncol. 1995;57:27-32.
14. Healy DL, Burger HG, Mamers P, et al. Elevated serum inhibin concentrations in postmenopausal women with ovarian tumors. N Engl J Med. 1993;329:1539-1542.
15. Burger HG, Fuller PJ, Chu S, et al. The inhibins and ovarian cancer. Mol Cell Endocrinol. 2001;180:145-148.
16. Gagne LJ, Colacchio T, Longnecker DS. Simultaneous mucinous cystadenoma of ovary and mucinous cystadenocarcinoma of pancreas. Int J Pancreatol. 2000;28:9-13.
17. Koprowski H, Steplewski Z, Mitchell K, et al. Colorectal carcinoma antigen detected by hybridoma antibodies. Somat Cell Genet. 1979;5:957-962.
18. Borowitz MJ, Tuck FL, Sindelar WF, et al. Monoclonal antibodies against human pancreatic adenocarcinoma: distribution of DU-PAN-2 antigen on glandular epithelia and adenocarcinomas. J Natl Canc Inst. 1984;72:999-1005.
19. Tenti P, Aguzzi A, Riva C, et al. Ovarian mucinous tumors frequently express markers of gastric, intestinal, and pancreatobiliary epithelial cells. Cancer. 1992;69:2131-2142.
20. Toyoshima H, Hunter T. p27, a novel inhibitor of G1 cyclin-CDK protein kinase activity, is related to p21. Cell. 1994;78:67-74.
21. Lu CD, Morita S, Ishibashi T, et al. Loss of p27kip1 expression independently predicts poor prognosis for patients with respectable pancreatic adenocarcinoma. Cancer. 1999;85:1250-1260.
22. Hurteau JA, Allison BM, Brutkiewicz SA, et al. Expression and subcellular localization of the cyclin-dependent kinase inhibitor p27kip1 in epithelial ovarian cancer. Gynecol Oncol. 2001;83:292-298.
23. Saegusa M, Mschida D, Okayasu I. Possible associations among expression of p14ARF, p16INK4a, p21WAF1/CIP1, p27KIP1, and p53 accumulation and the balance of apoptosis and cell proliferation in ovarian carcinomas. Cancer. 2001;92:1177-1189.
24. Nagahama H, Hatakeyama S, Nakayama K, et al. Spatial and temporal expression patterns of the cyclin-dependent kinase (CDK) inhibitors p27kip1 and p57kip2 during mouse development. Anat Embryol. 2001; 203:77-87.
25. Barnes A, Pinder SE, Bell JA, et al. Expression of p27kip1 in breast cancer and its prognostic significance. J Pathol. 2003;201:451-459.
26. Liu XP, Kawauchi S, Oga A, et al. Combined examination pf p27kip1, p21waf1/cip1 and p53 expression allows precise estimation of prognosis in patients with gastric carcinoma. Histopathology. 2001;39:603-610.
27. Hartwell LH, Kastan MB. Cell cycle control and cancer. Science. 1994;266:1821-1828.